Auropharma Profile Page at
in.tradingview.com
Note -
Use Signature Field to put 3rd party links / website details / social media details which comes as a part of “Premium subscription” (Promoting 3rd Party Links apart from premium version –do check with the moderators as it could violate house rule...
Trading Strategy
Last Price@717
Plan A
Expect Bullish Move "If" stock holds in 705-709 zone with strict stops below 695
Targets- 760/775/790
Plan B
Sell Below 695 with strict stops above 720
Target - 620 / 630
Thanks for watching the video.
Wait for breakout of any trendline. If continues above 50Ma with good momentum then buy can be initiated.. But remember its still in sellers zone.. break below the lower trendline may lead the price lower.
AUROBINDO PHARMA HAS FORMED A WEDGE SHAPE.
THERE IS A SELL SIGNAL.
IF THE WEDGE IS BROKEN, THEN EXPECT THE PRICE TO REACH 350 LVL.
IF IT BREAKS ABOVE, THEN THE PRICE MAY RETRACE TO 510.
Long if it breaks the high of the previous day with a stop loss at the previous day's low.
Short if it breaks the low of the previous day with a stop loss at the previous day's high.
In case of gap up above the previous day's high or gap down below the previous day's low, please avoid buying it or selling it respectively. Follow the ending of the candle formed...
Follow on twitter/telegram @piyushrawtani for live trading ideas.
AUROPHARMA has closed below a weekly support level and expected to test 390 levels in coming week.
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
AUROPHARMA
